Tachyphylaxis after Repeated Antidepressant Drug Exposure in Patients with Recurrent Major Depressive Disorder
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Objective: The aim of this post hoc analysis was to examine whether tachyphylaxis occurs after repeated courses of antidepressant drug therapy. Method: 276 patients with major depressive disorder (MDD) were treated with sertraline (150–200 mg daily) for 8 weeks. Patients with persistent MDD after sertraline therapy were randomized to continuation therapy with either sertraline plus atomoxetine (n = 72) or sertraline plus placebo (n = 74) for 8 additional weeks. Logistic regression was used to test the hypothesis that an increase in prior antidepressant drug exposure is associated with a reduced responsiveness to sertraline therapy. Results: The number of prior antidepressant drug exposures was negatively associated with response to initial sertraline therapy (odds ratio = 0.81, p = 0.0035). The odds ratio indicates a 19.9% reduced likelihood of response with each prior antidepressant treatment trial. In contrast, the number of prior antidepressant treatment trials was not associated with response to continuation sertraline plus atomoxetine or sertraline plus placebo therapy. Conclusion: This observation supports the hypothesis that tachyphylaxis may develop after repeated antidepressant drug trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior use of AD has been found to be related to resistance to AD that differed from those administered during the first trials.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [25]
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationAllelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
Wilamowska (2010) · doi:10.1001/archpsyc.1988.01800320058007 · Cited by 2,115 · cited 1×
“was used to confirm diagnostic eligibility for the study. Symptom severity was assessed using the 17-item Hamilton Depression Rating (HAM-D 17) scale [”
MethodGoldapple, K., Segal, Z., Garson, C., Lau, M., Bieling, P., Kennedy, S., & Mayberg, H. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.34 · Cited by 1,068
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Self-citationRemission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
Smeraldi, E., Zanardi, R., Benedetti, F., Bella, D. D., Perez, J., & Catalano, M. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000425 · Cited by 614 · cited 1×
“There is considerable debate as to whether tachyphylaxis to antidepressant drug therapy results from a genetic predisposition [”
BackgroundTreatment-Resistant Depression
(2015) · Encyclopedia of Psychopharmacology · doi:10.1007/978-3-642-36172-2_200431 · Cited by 488
Pollock, B. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00132-9 · Cited by 415
Research works printed but not linked: 7
- 10.1016%2fj.jad.2005.06.011 · DOI
- 10.4088%2fjcp.v68n1014 · DOI · Paper page
- 10.4088%2fjcp.1007e23 · doi:10.4088/jcp.1007e23
- 10.1016%2f0306-9877%2884%2990018-5 · DOI · Paper page
- 10.1176%2fappi.ajp.163.11.1905 · doi:10.1176/appi.ajp.163.11.1905 · Paper page
- 10.1176%2fappi.ajp.163.7.1161 · doi:10.1176/appi.ajp.163.7.1161 · Paper page
- 10.1176%2fappi.ajp.163.9.1531 · DOI
Cited by
Treatment selection in depression.
Cohen, Z. D., & DeRubeis, R. J. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084746 · Cited by 435
“Prior exposure to ADMs and history of nonresponse to ADMs have each been found consistently to predict poor response to future courses of antidepressants (Amsterdam et al. 2009, 2016; Amsterdam & Shults 2009; Byrne & Rothschild 1998).”
BackgroundBaldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Kim, T., Xu, C., & Amsterdam, J. D. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.028 · Cited by 190
Self-citationRoss, E. L., Zivin, K., & Maixner, D. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0768 · Cited by 150
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
“Followinga8 week, randomized, double-blind study comparing the efficacy and tolerability of escitalopram (10–20 mg/day; N=148) to that of venlafaxine extended release (75–150 mg/day; N=145) in primary care patients with MDD, at the end of the 1 week run-out period (week 9), a total of 23 symptoms were reported on the…”
InfluentialAn adaptationist perspective on the etiology of depression
Durisko, Z., Mulsant, B. H., & Andrews, P. W. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.09.032 · Cited by 140
“Similarly, there is a growing body of research suggesting that when they are used in the long-term as a maintenance treatment, antidepressants can lose efficacy (i.e., tachyphylaxis; Amsterdam et al., 2009; Byrne and Rothschild, 1998; Targum, 2014), and may even result in chronic and treatment-resistant depression (i.”
BackgroundRational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Pigott, H. E., Kim, T., Xu, C., Kirsch, I., & Amsterdam, J. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-063095 · Cited by 93
Self-citationFava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
Hengartner, M. P. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320921694 · Cited by 72
Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept
Hara, C., Wakabayashi, T., Fukushima, Y., Sayanagi, K., Kawasaki, R., Sato, S., Sakaguchi, H., & Nishida, K. (2019) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-019-04456-2 · Cited by 70
Influence of Age on Effectiveness and Tolerability of Electroconvulsive Therapy
Damm, J., Eser, D., Schüle, C., Obermeier, M., Möller, H.-J., Rupprecht, R., & Baghai, T. C. (2010) · The Journal of ECT · doi:10.1097/yct.0b013e3181cadbf5 · Cited by 62
Early onset of depression and treatment outcome in patients with major depressive disorder
Herzog, D. P., Wagner, S., Engelmann, J., Treccani, G., Dreimüller, N., Müller, M. B., Tadic, A., Murck, H., & Lieb, K. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.048 · Cited by 52
Ross, E. L., Vijan, S., Miller, E. M., Valenstein, M., & Zivin, K. (2019) · Annals of Internal Medicine · doi:10.7326/m18-1480 · Cited by 50
“Third, we assessed calculating efficacy of treatments after first-line SGA and CBT on the basis of a 19% reduction in odds of response and remission with each successive treatment (57), rather than using STAR*D data (31).”
Tachyphylaxis in major depressive disorder: A review of the current state of research
Kinrys, G., Gold, A. K., Pisano, V. D., Freeman, M. P., Papakostas, G. I., Mischoulon, D., Nierenberg, A. A., & Fava, M. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.10.357 · Cited by 45
Self-citationTachyphylaxis/ tolerance to antidepressive medications: a review.
Katz, G. (2011) · PubMed · Cited by 23
Blumberger, D. M., Mulsant, B. H., Emeremni, C. A., Houck, P. R., Andreescu, C., Mazumdar, S., Whyte, E. M., Rothschild, A. J., Flint, A. J., & Meyers, B. S. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.01.003 · Cited by 23
“…patients who fail to respond to a previous adequate course of pharmacotherapy are significantly less likely to respond to treatment than treatment naïve patients or than those who have been exposed to an inadequate course (Amsterdam et al., 2009; Hennings et al., 2009; Tew et al., 2006).”
BackgroundLucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 24
Failure to Respond after Reinstatement of Antidepressant Medication: A Systematic Review
Bosman, R. C., Waumans, R. C., Jacobs, G. E., Oude Voshaar, R. C., Muntingh, A. D. T., Batelaan, N. M., & van Balkom, A. J. L. M. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491550 · Cited by 21
Saunders, R., Cohen, Z. D., Ambler, G., DeRubeis, R. J., Wiles, N., Kessler, D., Gilbody, S., Hollon, S. D., Kendrick, T., Watkins, E., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121295 · Cited by 21
Hunter, A. M., Cook, I. A., & Leuchter, A. F. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181faa474 · Cited by 20
Amsterdam, J. D., Lorenzo‐Luaces, L., & DeRubeis, R. J. (2016) · Bipolar Disorders · doi:10.1111/bdi.12442 · Cited by 18
Self-citationSeabrooke, S., & O’Donnell, M. J. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00408.2012 · Cited by 18
Hunter, A. M., Cook, I. A., & Leuchter, A. F. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.02.005 · Cited by 17
“, decrements in response with successive drug trials (Amsterdam et al., 2009), bolster this view.”
BackgroundAmsterdam, J. D., & Kim, T. T. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001049 · Cited by 17
Self-citationHunter, A. M., Cook, I. A., Tartter, M. A., Sharma, S. K., Disse, G. D., & Leuchter, A. F. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4047-2 · Cited by 16
“The current results are consistent with previous studies showing associations between prior antidepressant exposure and poor outcome regardless of clinical or demographic variables, including degree of prior treatment resistance (Amsterdam et al. 1994, 2009).”
ResultKatz, G. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02231.x · Cited by 12
“The clinical aspects of the theory of tachyphylaxis as ‘stepwise’ receptor desensitization during unipolar major depression were studied by Amsterdam and colleagues.(16) The results indicated that the number of prior antidepressant drug exposures was negatively associated with response to initial sertraline therapy an…”
BackgroundAndrews, P. W., & Amsterdam, J. D. (2020) · Psychiatria Polska · doi:10.12740/pp/120084 · Cited by 11
Self-citationHunter, A. M., Cook, I. A., Abrams, M., & Leuchter, A. F. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.09.016 · Cited by 10
“In the context of antidepressant treatment, a clinical literature suggests that the clinical efficacy of antidepressant treatment may decrease over prolonged or repeated administrations [11], such as in ‘tachyphylaxis’ [12–16].”
BackgroundCarter, E., Banerjee, S., Alexopoulos, G. S., Bingham, K. S., Marino, P., Meyers, B. S., Mulsant, B. H., Neufeld, N. H., Rothschild, A. J., Voineskos, A. N., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.013 · Cited by 6
“A history of recurrence is one of the most robust predictors of future recurrence of MDD (Buckman et al., 2018; Hardeveld et al., 2010).”
InfluentialKim, T. T., & Amsterdam, J. D. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13518 · Cited by 5
“These findings are consistent with prior reports by Amsterdam et al.(38) and Rush et al.”
ResultSelf-citationAmsterdam, J. D., & Lorenzo‐Luaces, L. (2018) · Psychiatria Polska · doi:10.12740/pp/98961 · Cited by 4
Self-citationXu, C., Kim, T. T., Kirsch, I., Plöderl, M., Amsterdam, J. D., & Pigott, H. E. (2025) · medRxiv · doi:10.1101/2025.02.10.25321991 · Cited by 2
Self-citationGönül, A. S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.068 · Cited by 1
Evidence of new-onset depression among persons with migraine after discontinuing antidepressants
Kious, B. M., & Bakian, A. V. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112990 · Cited by 1
Antidepressant-Antianxiety Agents
Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_4 · Cited by 1
Amsterdam, J. D., Williams, D., Michelson, D., Adler, L. A., Dunner, D. L., Nierenberg, A. A., Reimherr, F. W., Schatzberg, A. F., Luca, V. D., Annesi, G., et al. (2009) · Neuropsychobiology · doi:10.1159/000235637
Self-citationCurrent awareness: Pharmacoepidemiology and drug safety
(2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1848
Current awareness in human psychopharmacology
(2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1061
Les manifestations cliniques associées à la toxicité comportementale
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00003-0
Metadata
- Authors
- Amsterdam, J. D., Williams, D., Michelson, D., Adler, L. A., Dunner, D. L., Nierenberg, A. A., Reimherr, F. W., & Schatzberg, A. F.
- Affiliations
- University of Pennsylvania (US)
- Eli Lilly (United States) (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- New York University (US)
- Harvard University (US)
- University of Utah (US)
- Stanford Medicine (US)
- Venue
- Neuropsychobiology
- Publisher
- S. Karger AG
- Published
- 2009
- Volume
- 59
- Issue
- 4
- Pages
- 227-233
- ISSN
- 0302-282X (ISSN-L)
- 1423-0224
- OpenAlex
- W2014544184
- Cited by
- 39
- References
- 39
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 4 · 2019: 5 · 2018: 5 · 2016: 1 · 2015: 1 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Neuropsychobiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- tachyphylaxis, antidepressant resistance, recurrent major depressive disorder, sertraline, atomoxetine, treatment response, continuation treatment, selective serotonin reuptake inhibitors
- MeSH terms
- Atomoxetine Hydrochloride, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Propylamines, Recurrence, Tachyphylaxis, Logistic Models, Odds Ratio, Treatment Outcome, Adrenergic Uptake Inhibitors, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.